About Phanes Therapeutics
Phanes Therapeutics, Inc. is a biotech company focused on innovative drug discovery and early development in immuno-oncology and eye disease. Our mission is to become a major source of innovation in the biopharma industry. The way we focus on science, the disruptive technologies we develop, and the revolutionary approaches we bring help open up new possibilities in drug discovery. At Phanes, we bring innovation that illuminates the path to cure.
The company has two technology platforms, the PACbodyTM and the ATACCbodyTM.
The PACbodyTM platform allows for construction of native IgG-like bispecific antibodies (PACbodies) with drug-like properties. PACbodies can be designed to be fit for platform in the conventional manufacturing process for monoclonal antibodies.
The ATACCbodyTM platform allows for construction of conjugated IgG-like bispecific antibodies (ATACCbodies) whose activities are modulated by the environment they are in. The technology is designed for targeting solid tumors using immuno-oncology molecules with minimal risk of cytokine release syndrome (CRS) seen in traditional immuno-oncology therapies.